Skip to main content
Premium Trial:

Request an Annual Quote

Provista Raising $5M in Series A Financing

NEW YORK (GenomeWeb News) – Provista Diagnostics today announced it has entered into purchase agreements with institutional investors to raise $5 million in a Series A Preferred financing.

The funds will go mainly toward the completion of a confirmatory clinical trial and 510(k) submission to the US Food and Drug Administration of its breast cancer test. The remainder will be used to repay outstanding short-term debt obligations, the Phoenix-based firm said.

The firm's BT test, which is used in conjunction with mammography, is its first product and detects biomarkers in blood that are associated with early breast cancer. Provista, which focuses on oncology, is also developing a lung cancer test and an ovarian cancer test.

The company also named additions to its board of directors in connection to the financing: Jeffrey Gilman, an executive at investment advisor Louis-Dreyfus Family Office; Anne Busquet, a principal at consulting firm AMB Advisors; and John Macaskill, managing director of Groton Partners, a merchant bank.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.